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Summary
Objective: To demonstrate the potential clinical applicability of the PCR technique to
the early detection of bacterial resistance in Streptococcus pneumoniae.
Methods: We studied 153 samples of S. pneumoniae, isolated from different ana-
tomic sites, using polymerase chain reaction (PCR) for the detection of specific
amplicons from genes that code for penicillin-binding proteins (PBP) 1a, 2b and
2x, which are responsible for penicillin resistance in this organism. The occurrence of
these mutated genes was correlated with the minimum inhibitory concentration (MIC)
of penicillin, determined by the agar dilution test.
Results: The rate of penicillin resistance in S. pneumoniae in Porto Alegre, Brazil was
22.8% (16.3% intermediate resistance and 6.5% high resistance). In a statistically
significant proportion of cases ( p < 0.05), penicillin-susceptible samples had no
amplicons, intermediate samples had only one (generally from PBP 2x), and highly
resistant samples had amplicons from all three PBPs investigated.* Corresponding author. Tel.: +55 5130291201; fax: +55 5133312076.
E-mail addresses: ewzettler@terra.com.br, ezettler@pucrs.br (E.W. Zettler).
1201-9712/$32.00 # 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.ijid.2005.04.005
Determination of penicillin resistance in Streptococcus pneumoniae isolates 111Introduction
Streptococcus pneumoniae is the leading cause of
community-acquired infection all over the world
and is associated with a world mortality rate of
three to five million deaths a year.1 In the United
States, it is responsible for 500 000 annual cases of
pneumonia, 50 000 cases of bacteremia, 3000 cases
of meningitis and about seven million cases of acute
otitis media.2,3
The resistance of the pneumococcus to penicillin
has increased significantly in recent years, particu-
larly in European countries like Spain, France and
Hungary, where it is as high as 71%.4,5 In the United
States it reaches 44% in some states,6,7 and in Asia
alarming rates of between 70 and 78% of resistance
have been found in Hong Kong, South Korea and
Taiwan.8,9
In Brazil, some studies have shown levels of resis-
tance close to 20%,10—12 but a more recent study
detected reduced susceptibility to penicillin in
42.1% (26.8% of intermediate resistance and 15.3%
of high resistance) of the isolates from three Latin
American countries (Argentina, Brazil and Mexico).13
The resistance of S. pneumoniae to beta-lactam
antimicrobials is solely due to altered penicillin-
binding protein (PBP) genes, their natural target,
which prevents them from binding and makes them
insensitive to beta-lactam agents, i.e., decreases
their binding affinity for these drugs. In highly resis-
tant isolates, there is a reduced ability to bind to the
antibiotic in at least three of the five existing PBPs:
PBP 1a, PBP 2x and PBP 2b.14—16
With the growth of resistance of this pneumococ-
cus, it has become crucial to develop a quick and
reliable diagnostic technique, which can guide early
and effective treatment in cases of infection with
resistant strains.Methods
Bacterial samples
An analysis of 197 clinical isolates of S. pneumoniae
provided by the Microbiology Laboratories of the
hospitals from Porto Alegre, Brazil, which contrib-
uted to the study (Hospital de Clı´nicas de PortoAlegre, Irmandade Santa Casa de Miserico´rdia de
Porto Alegre, Hospital da Crianc¸a Santo Antoˆnio,
Hospital Ma˜e Deus, Hospital Moinhos de Vento, Hos-
pital Nossa Senhora da Conceic¸a˜o, and Hospital Sa˜o
Lucas, PUCRS) was carried out; identification was by
standard laboratory techniques.17
Antimicrobial susceptibility test
The minimum inhibitory concentration (MIC) to
penicillin was measured using the agar dilution test
in Mueller—Hinton agar medium (Oxoid Unipath Ltd,
Hampshire, UK) containing 5% defibrinated sheep’s
blood. The breakpoints were those published by the
National Committee for Clinical Laboratory Stan-
dards (NCCLS),17 namely: susceptible (MIC  0.06
mg/mL), intermediate resistance (MIC 0.12 to
1.0 mg/mL), and high resistance (MIC  2.0 mg/mL).
S. pneumoniae ATCC 49619 was used for quality
control of the susceptibility test.17
Polymerase chain reaction (PCR)
The samples isolated from the culture media were
simultaneously submitted to PCR for detection of
the lytA gene of S. pneumoniae, as described by
Ubukata et al.18 to confirm bacterial identification,
and specific amplicons of specific sizes using specific
primers from PBP 1a, 2b and 2x genes, according to
the protocol described by Jalal et al.19
Statistical analysis
Statistical analysis was carried out using the Chi-
square test (x2) applying Yates correction, with a
level of significance of 95% (p < 0.05).Results
Of the 197 samples initially identified as S. pneu-
moniae by microbiology laboratories of the hospi-
tals, 34 (17.3%) were excluded from the study
because they failed to grow in the culture medium
after being thawed (bacterial death), or because
the identification of the bacterial species was not
confirmed by microbiological tests.Conclusion: These results suggest that penicillin resistance in S. pneumoniae in
southern Brazil is on the increase, but is still lower than in other countries, and that
PCR could be used for its early detection.
# 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All
rights reserved.
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Figure 1 Agarose gel electrophoresis of PCR products
amplified using primers derived from the PBP 2b and PBP
2x genes of penicillin-susceptible Streptococcus pneumo-
niae. The sizes of these amplicons are 359 and 277 base
pairs, respectively. Lane MW:marker of molecular weight;
lane C: negative control; lanes 1, 2, 3, 5, 6, 7 and 8:
susceptible samples; lanes 9 and 10: intermediate sam-
ples; lane 4: highly resistant sample.
Table 1 Correlation of number of amplicons and level
of resistance.
Susceptible Intermediate Resistant
No amplicons 86 (72.8%)a 2 (8%) 0 (0%)
1 amplicon 32 (27.2%) 18 (72%)b 0 (0%)
2 amplicons 0 (0%) 4 (16%)c 1 (10%)
3 amplicons 0 (0%) 1 (4%) 9 (90%)d
Total 118 25 10
a Comparison susceptible  intermediate samples with no
amplicons: p < 0.05.
b Comparison susceptible  intermediate samples with 1
amplicon: p < 0.05.
c Comparison intermediate  resistant samples with 2
amplicons: p = non-significant.
d Comparision intermediate  resistant samples with 3
amplicons: p < 0.05.The remaining 163 samples were simultaneously
submitted to tests to determine the MIC and to PCR
to detect specific amplicons of specific sizes using
specific primers from PBP 1a, 2b and 2x genes
(Figure 1) and amplification of the lytA gene to
confirm the bacterial identification.
Origin of the strains
The strains of S. pneumoniaewere isolated from the
following clinical materials: sputum (37.9%), blood
culture (17.2%), cerebrospinal fluid (12.9%), tra-
cheal aspirate (10.3%), pleural fluid (6.0%), nasal
fluid (5.1%), ocular fluid (4.3%), bronchoalveolar
lavage (2.6%), abdominal fluid (2.6%), and ear fluid
(0.8%). The age range of the patients from whom
the isolates were obtained was 18 months to 86
years.
PCR for identification of lytA gene
The 163 samples identified as S. pneumoniae by
standard microbiological techniques were sub-
mitted to PCR for detection of the lytA gene in
order to confirm the bacterial identification. The
presence of lytA gene was verified in 153 samples.
The remaining 10 samples were excluded from the
final analysis.
Agar dilution test
The distribution of the resistance of S. pneumoniae
in the remaining 153 samples of the study, tested by
the agar dilution test according to their MIC, was the
following: susceptible, 118 samples (77.1%); inter-
mediate resistance, 25 samples (16.3%); high resis-
tance, 10 samples (6.5%).Correlation of number of amplicons from
PBP and level of resistance
The number of amplicons of specific sizes using
specific primers from PBP 1a, 2b and 2x in each
sample was correlated with their degree of resis-
tance as determined by the MIC (Table 1). The
proportion of susceptible, intermediately resistant
and highly resistant samples with a particular num-
ber of amplicons was compared among themselves,
and the statistical significance of these differences
was assessed.
Samples without amplicons: no resistant samples
were found in this group; comparison of su-
sceptible  intermediate samples: x2 = 33.89
(p < 0.0005).
Samples with 1 amplicon: no resistant samples
were found in this group; comparison of su-
sceptible  intermediate samples: x2 = 16.277
(p < 0.0005).
Samples with 2 amplicons: no susceptible samples
were found in this group; comparison of
intermediate  resistant samples: x2 = 0.006
(p = 0.942).
Samples with 3 amplicons: no susceptible samples
were found in this group; comparison of
intermediate  resistant samples: x2 = 21.843
(p < 0.0005).
Correlation of amplicons of each PBP and
level of resistance
The presence of amplicons from each of the three
PBPs was then independently correlated with the
resistance levels determined by the MIC, as shown in
Table 2.
Amplicons from PBP 2b: no susceptible samples
were found in this group; comparison of
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Table 2 Correlation of amplicons from each PBP and
level of resistance.
Susceptible Intermediate Resistant
PBP 2b 0 (0%) 7 (28%) 10 (100%)a
PBP 2x 32 (27.2%) 21 (84%)b 10 (100%)c,d
PBP 1a 0 (0%) 1 (4%) 9 (90%)a
Total 118 25 10
a Comparison intermediate  resistant: p < 0.05.
b Comparison susceptible  intermediate: p < 0.05.
c Comparison susceptible  resistant: p < 0.05.
d Comparison intermediate  resistant: p = non-significant.intermediate  resistant samples: x2 = 18.308
(p < 0.0005).
Amplicons from PBP 2x: comparison of su-
sceptible  intermediate samples: x2 = 25.304
(p < 0.0005); comparison of susceptible  resis-
tant samples: x2 = 18.388 ( p < 0.0005); com-
parison of intermediate  resistant samples:
x2 = 0.572 ( p = 0.4539).
Amplicons from PBP 1a: no susceptible samples
were found in this group; comparison of
intermediate  resistant samples: x2 = 21.843
(p < 0.0005).Discussion
The resistance of S. pneumoniae to penicillin in Porto
Alegre, a city of 1.5 million inhabitants in southern
Brazil, has increased considerably in the years since
the study by Chatkin et al.20 that showed only 3.2%,
reaching 22.8% in the period of our study. This rate is
close to that found by Sessegolo et al.10 and Levin
et al.11 in the state of Sa˜o Paulo in the 1990s (24%).
More recently, Mendes et al.13 studied pneumococcal
samples isolated in three Latin American countries
(Argentina, Brazil and Mexico) and found even higher
levels of resistance, which reached 42.1%.
It should be highlighted that most of the resistant
pneumococcal strains that we found showed inter-
mediate resistance to penicillin (16.3%), and only
6.5% showed high resistance. As previously reported
by several authors, samples with intermediate resis-
tance have shown good clinical response to penicil-
lin in high doses,21,22 while the highly resistant ones
can lead to greater morbidity and mortality.23,24
As compared to surveys carried out in other
countries, the resistance of the pneumococci in
our community is still low. In the United States,
for example, a recent epidemiological report, pub-
lished by Karlowsky et al.6 investigating 27 828
samples of S. pneumoniae isolated in several
American states, showed 18.4% of isolates had some
degree of penicillin resistance.In the present study, a significant correlation was
found between the presence of specific amplicons of
specific sizes using specific primers from the PBP
genes of S. pneumoniae and the levels of penicillin
resistance in vitro determined by the MIC. The
susceptible samples were characterized by the
absence of amplicons, those of intermediate resis-
tance by the occurrence of only one amplicon,
usually from PBP 2x, and the highly resistant ones
by the presence of amplicons from all three PBPs.
The presence of amplicons from PBP 1a or PBP 2b
occurred in a significantly greater number of sam-
ples with high resistance than those with intermedi-
ate resistance. We were, however, unable to
discriminate between samples with intermediate
or high resistance by the presence or not of ampli-
cons from PBP 2x. The combination of amplicons
from two or three PBPs was significantly correlated
with the expression of high resistance to penicillin.
Without sequence data it is presumptuous to state
that samples had specific numbers of mutations
within PBP genes based upon targeted PCR results.
These results are in agreement with others stu-
dies demonstrating that the mutations in the PBP 2x
genome lead to a low level of penicillin resistance,
while high penicillin resistance requires genetic
alterations in both PBP 1a and 2b.25—29
Ubukata et al.18 investigating the presence of
mutations in the genes of PBP 2b in 1062 clinical
isolates of S. pneumoniae through PCR, found cor-
relation with the findings of MIC of penicillin in
98.9% of the susceptible samples and 70.3% of the
resistant ones.
Nagai et al.30 assessed the presence of mutations
in PBP 2b and 2x in 218 samples of S. pneumoniae
isolated from children in Japan. Mutations in PBP 2x
were detected in several strains with intermediate
resistance to penicillin. In 41.3% of the cefotaxime-
susceptible samples, mutations in the genes of PBP
2x were detected, suggesting that the mechanisms
of resistance can occur even in strains which are
susceptible to the antimicrobials and may precede
the resistance detected in vitro.
In our study, these results were reproduced, and
the presence of amplicons from PBP 2x was detected
in 84% of samples with intermediate resistance to
penicillin, showing that this may be a marker of a
lower level of resistance. Thus, it was not possible to
discriminate between intermediately and highly
resistant samples using amplicons from PBP 2x
solely, but it was possible to differentiate signifi-
cantly the susceptible strains from those that had
some degree of resistance (intermediate or high).
The majority of intermediately resistant isolates
will in fact contain mutations within PBP 2b and will
contain key substitutions that are highly associated
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et al.31 using a semi-nested PCR strategy (one based
on the amplification of the pneumococcal PBP 2b
gene to detect intermediately penicillin-resistant
S. pneumoniae), that the positive predictive value
and the negative predictive value of the assay were
each 100%.
Others studies have shown that molecular
approaches are excellent at verifying fully suscep-
tible strains.18,19 This is as expected because of
the genetic conservation of penicillin-susceptible
genes. On the other hand, PCR-based systems had
difficulty detecting resistant isolates. All of the
resistant isolates identified were truly resistant,
but those strains with a sequence not encompassed
by the primers were not amplified and thus gave
false-negative results.
O’Neill et al.27 performed a PCR-restriction frag-
ment length polymorphism strategy directed against
the PBP 2b gene for identification of penicillin
susceptibility. By using conventional definitions of
‘not resistant’ and ‘not susceptible’, the sensitiv-
ities were 97.5% and 94.4%, the specificities were
100% and 98.9%, the positive predictive values were
100% and 94.4%, and the negative predictive values
were 93.1% and 98.9%, respectively. They concluded
that this technique could allow susceptible (MIC,
<0.1 mg/L) and resistant (MIC,>1 mg/L) isolates to
be distinguished in a single PCR.
The detection of PBP 1a by PCR was used by du
Plessis et al.28 in 183 clinical isolates of S. pneu-
moniae, obtaining an agreement of 98.3% between
the results of PCR and penicillin MIC data. The
positive and negative predictive values of this
molecular technique were 100% in detecting sam-
ples with MIC 1 mg/mL. However, their results
indicated that 3.6% of the intermediate isolates
may be misclassified as susceptible when this PCR
assay is used.
A study by Smith and Klugman,29 examining highly
resistant (MIC 4 mg/mL) pneumococcal strains,
demonstrated that the higher the MIC, the greater
the number of alterations in the sequence of nucleo-
tides of PBP 1a, and that these mutations are com-
mon to all resistant isolates, thus being the most
critical factor in the development of bacterial resis-
tance in high degree.
Similarly, in our samples with high penicillin
resistance we found the presence of the amplicon
from PBP 1a in 90% of the cases (9/10 cases). In only
one sample, classified as highly resistant to penicil-
lin according to the NCCLS guidelines,17 was no
amplicon from PBP 1a detected. This sample had
MIC = 2.0 mg/mL, a value that is exactly at the
breakpoint between intermediate and high resis-
tance. This difference between phenotypic andgenetic methods did not, however, affect the over-
all effectiveness of the method.
The only previous study that has investigated the
simultaneouspresence ofmutations in the threePBPs
(1a, 2b and 2x) related to bacterial resistance was
performed by Jalal et al.19 They studied 230 clinical
isolates of S. pneumoniae and identified 93% of sus-
ceptible, 85% of intermediate and 100% of highly
resistant samples through PCR. However, mutations
in the PBP 1a did not correlatewell with resistance in
vitro and so it was excluded from the data analysis,
which was confined to the assessment of PBP 2b and
2x. Nevertheless, the results obtained were consid-
ered as potentially clinically useful, even though a
more in-depth statistical analysis was not done.
A major factor in approaching a patient with
pneumococcal infection is early treatment with
antimicrobials, which can be crucial in the progress
and prognosis of the disease.32,33 By standard micro-
biological methods it takes at least 24 hours to grow
and identify the organism in culture media and an
additional 24 hours to perform the susceptibility
tests.17 All the steps of the PCR technique described
here can be performed in up to 16 hours, which
permits the confirmation of the etiological agent
and the identification of its level of resistance
simultaneously, thus allowing much faster and more
effective treatment.
Molecular diagnosis of penicillin resistance is
troublesome because of the presence of the multi-
ple PBPs involved in the development of resistance.
With this study we have demonstrated the potential
clinical applicability of the PCR technique to the
early detection of bacterial resistance of S. pneu-
moniae, a technique that is fast and easy to perform
in properly equipped laboratories. Further studies
could well determine which PBPs are the best target
in a PCR-based diagnostic assay aimed at the detec-
tion of all pneumococci with resistance to beta-
lactam antibiotics.
Conflict of interest: No conflict of interest to
declare.
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